| European Case Law Identifier: | ECLI:EP:BA:2017:T186816.20171108 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 08 November 2017 | ||||||||
| Case number: | T 1868/16 | ||||||||
| Application number: | 10175197.2 | ||||||||
| IPC class: | A61K 31/436 A61P 35/00 A61P 35/04 A61K 38/31 A61K 45/06 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | mTOR inhibitors in the treatment of endocrine tumors | ||||||||
| Applicant name: | Novartis AG | ||||||||
| Opponent name: | Teva Pharmaceutical Industries Ltd. Synthon B.V./Genthon B.V. Ethypharm Maiwald Patent- und Rechtsanwaltsgesellschaft mbH Generics [UK] Limited (trading as Mylan) |
||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Sufficiency of disclosure - main request (no) Auxiliary requests submitted with reply to the statment of grounds of appeal - admitted (yes) Late filed auxiliary request 6 - admitted (no) Sufficeincy of disclosure - auxiliary requests (no) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t161868eu1.html
Date retrieved: 17 May 2021